Vertex and CRISPR Therapeutics to develop gene-editing treatment

US-based Vertex Pharmaceuticals and CRISPR Therapeutics have revealed plans to jointly develop and commercialise an investigational gene-editing treatment.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Vertex signs $100m CRISPR deal to use sickle cell treatment

14 December 2023 Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.

Americas

Vertex to buy diabetes biotech firm for $950m

4 September 2019 US-based Vertex Pharmaceuticals has announced it will pay $950 million to acquire Semma Therapeutics, a biotechnology company focused on researching a cure for Type 1 diabetes.

Americas

FDA lifts hold on first human CRISPR trial

17 October 2018 The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.